Metraipolis › archive › dc_0101bb7e5586

Selected adverse events during the 12-week induction period of a phase III trial of vunakizumab: an exploratory post-hoc analysis — Europe PMC PMID:42952621

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42952621
DOI
10.3389/fimmu.2026.1894231
License (as archived)
solo-consultazione
Archived
2026-10-31T10:31:46.547Z
SHA-256 of the archived text
e502a63b29d6304f2f301843125a1bb005067925bfc36c7d8b77034f4021e885
Stable URL of this page
https://metraipolis.com/documento/dc_0101bb7e5586

How to cite

Selected adverse events during the 12-week induction period of a phase III trial of vunakizumab: an exploratory post-hoc analysis — Europe PMC PMID:42952621 — Europe PMC (en), https://europepmc.org/article/MED/42952621 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0101bb7e5586 (Metraipolis archive dc_0101bb7e5586, sha256 e502a63b29d6304f2f301843125a1bb005067925bfc36c7d8b77034f4021e885)
BibTeX
@misc{dc0101bb7e5586,
  title = {Selected adverse events during the 12-week induction period of a phase III trial of vunakizumab: an exploratory post-hoc analysis — Europe PMC PMID:42952621},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42952621},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0101bb7e5586; sha256 e502a63b29d6304f2f301843125a1bb005067925bfc36c7d8b77034f4021e885},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42952621. Agents can read the archived copy with the MCP tool read_document.